Business Context and Reporting Period
This Form 8-K was filed by Catalyst Biosciences, Inc. (CBIO) on December 19, 2019, reporting events occurring on December 18, 2019. The filing details a material definitive agreement entered into with Biogen International GmbH.
Key Financial Metrics and Transaction Terms
- Up-Front Payment: $15 million cash payment received from Biogen.
- Milestone Payments: Eligible for up to $340 million in clinical, regulatory, and commercial milestones.
- Royalties: High-single digit to low-double digit tiered royalties on net sales of Products.
- Reimbursements: Biogen will reimburse the Company for pre-clinical and manufacturing activities.
- Financial Statements: This filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period.
Material Changes and Agreement Details
The Company granted Biogen a worldwide, exclusive, sublicensable license to develop, manufacture, and commercialize pegylated CB 2782 (CB 2782-PEG) and other compounds targeting complement factor 3. The primary therapeutic indication is geographic atrophy (GA) associated with dry age-related macular degeneration (dry AMD).
- Roles: Catalyst Biosciences will perform pre-clinical and manufacturing activities. Biogen is solely responsible for IND-enabling activities, worldwide clinical development, and commercialization.
- Regulatory Control: Biogen has sole control over regulatory submissions and associated costs.
- Termination: Biogen may terminate the agreement at will with 60 days' notice. Either party may terminate for material breach (uncured for 90 days) or insolvency.
Outlook, Risks, and Contingencies
The agreement remains in effect until the expiry of all royalty obligations. The Company's future revenue from this deal is contingent upon Biogen achieving specific clinical, regulatory, and commercial milestones, as well as generating net sales of the Products. The filing notes that Biogen has the right to terminate the agreement at will, which represents a significant contingency for the realization of milestone and royalty payments.
Investor Verification Checklist
- Verify the receipt of the $15 million up-front payment in the Company's cash flow statement for the quarter ended December 31, 2019.
- Review the full text of the License and Collaboration Agreement (to be filed as an exhibit to the 10-K) for specific definitions of milestone triggers and royalty tiers.
- Assess the impact of the "termination at will" clause on the valuation of the $340 million in potential milestones.
- Confirm the specific scope of "pre-clinical and manufacturing activities" for which reimbursement is expected.